Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma | Dong et al. Journal of Translational Medicine 2010 8 81 http content 8 1 81 RESEARCH JOURNAL OF TRANSLATIONAL MEDICINE Open Access Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma Jun Dong1t Bo-hang ZengH Li-hua Xu2 3 Jun-ye Wang3 4 Man-Zhi Li2 3 Mu-sheng Zeng2 3 Wan-li Liu3 5 Abstract Background The oncogene CDC25B phosphatase plays an important role in cancer cell growth. We have recently reported that patients with esophageal squamous cell carcinoma ESCC have significantly higher serum levels of CDC25B autoantibodies CDC25B-Abs than both healthy individuals and patients with other types of cancer however the potential diagnostic or prognostic significance of CDC25B-Abs is not clear. The aim of this study is to evaluate the clinical significance of serum CDC25B-Abs in patients with ESCC. Methods CDC25B autoantibodies were measured in sera from both 134 patients with primary ESCC and 134 healthy controls using a reverse capture enzyme-linked immunosorbent assay ELISA in which anti-CDC25B antibodies bound CDC25B antigen purified from Eca-109 ESCC tumor cells. The clinicopathologic significance of CDC25B serum autoantibodies was compared to that of the tumor markers carcinoembryonic antigen CEA squamous cell carcinoma antigen SCC-Ag and cytokeratin 19 fragment antigen 21-1 CYFRA21-1 . Results Higher levels of CDC25B autoantibodies were present in sera from patients with ESCC A450 1 7 SD than in sera from healthy control subjects A450 78 SD P . The area under the receiver operating characteristic ROC curve for CDC25B-Abs was 95 CI . The sensitivity and specificity of CDC25B-Abs for detection of ESCC were and respectively when CDC25-Abs-positive samples were defined as those with an A450 greater than the cut-off value of . Relatively few patients tested positive for the tumor markers CEA SCC-Ag and CYFRA21-1 .
